The FINANCIAL -- Novartis announced on December 21 that the World Health Organization (WHO) has granted prequalification for all three of its influenza...

Bristol-Myers Squibb Announces Appointment of Charles Bancroft as Acting Chief Financial Officer

by The FINANCIAL

December 14, 2009

The FINANCIAL -- Bristol-Myers Squibb Company (NYSE:BMY) has appointed Charles Bancroft as acting chief financial officer effective January 1, 2010...

TAK-085 Entered into Phase 3 Clinical Programs for Treatment of Hypertriglyceridemia in Japan

by The FINANCIAL

December 14, 2009

The FINANCIAL -- Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and Pronova BioPharma ASA (Lysaker, Norway, “Pronova”) on December 14 announced that...

Novo Nordisk starts phase 1 trial with oral insulin analogue

by The FINANCIAL

December 7, 2009

The FINANCIAL -- Novo Nordisk on December 7 announced that it has initiated its first phase 1 clinical trial with an oral...

Nplate(R) Data From MDS Studies Presented at ASH

by The FINANCIAL

December 7, 2009

The FINANCIAL -- Amgen Inc. (Nasdaq: AMGN) on December 6 announced results from three studies on the safety and efficacy of Nplate?? (romiplostim)...

Pharmacyclics Reports Interim Safety And Clinical Data From Phase I/II Trial Of PCI-24781 In Lymphom

by The FINANCIAL

December 7, 2009

The FINANCIAL -- Pharmacyclics, Inc. (Nasdaq: PCYC) on December 6 announced interim results from a Phase I/II study showing safety and clinical...

Visanne cleared for market launch in Europe as new treatment option for endometriosis

by The FINANCIAL

December 7, 2009

The FINANCIAL -- Bayer Schering Pharma AG, Germany, has successfully completed the decentralized part of drug approval procedure in Europe...

Johnson & Johnson: Fixed-dose rivaroxaban reduced long-term VTE recurrence

by The FINANCIAL

December 7, 2009

The FINANCIAL -- Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced on December 6 that results from the Phase...

Multaq Approved in the European Union for Patients with Atrial Fibrillation

by The FINANCIAL

November 30, 2009

The FINANCIAL -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on November 30 that the European Commission has granted marketing...

GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed

by The FINANCIAL

November 30, 2009

The FINANCIAL -- The London Organising Committee of the Olympic Games and Paralympic Games (LOCOG) on November 30 announces GlaxoSmithKline (GSK) as...

Bayer Starts Phase III Trial with Florbetaben

by The FINANCIAL

November 30, 2009

The FINANCIAL -- Bayer Schering Pharma AG, Germany, is progressing with the development of florbetaben to support Alzheimer diagnosis.

Ticagrelor (BRILINTA) demonstrated greater efficacy over clopidogrel in the most urgent clinical set

by The FINANCIAL

November 16, 2009

The FINANCIAL -- AstraZeneca (NYSE: AZN) on November 16 announced results of a PLATO sub-analysis in the most serious type of Acute...

Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA (ezetimibe) and VYTORIN

by The FINANCIAL

November 16, 2009

The FINANCIAL -- At the American Heart Association meeting on November 15, Merck & Co., Inc. said it is confident...

GSK and Nabi announce agreement for NicVAX, a vaccine for nicotine addiction

by The FINANCIAL

November 16, 2009

The FINANCIAL -- GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) on November 16 announcedan exclusive worldwide option and licensing agreement for...